Navigation Links
Neurocrine Biosciences Reports Second Quarter 2013 Results
Date:7/25/2013

in early July 2013. The study is a placebo-controlled, double-blind, parallel-design, multiple-dose, 12-week study assessing six-week dosing of NBI-98854 against placebo, followed by six weeks of open-label treatment with NBI-98854 in tardive dyskinesia patients with underlying schizophrenia or schizoaffective disorder. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the first six weeks of dosing. The study has incorporated a capsule formulation of NBI-98854. Top-line data from the placebo-controlled portion of this study is expected in September 2013.

The Kinect 2 Study is a 90 subject, placebo-controlled, double-blind, parallel-design, multiple-dose, six-week study assessing NBI-98854 against placebo in tardive dyskinesia patients with underlying mood disorders, schizophrenia and schizoaffective disorders, and gastrointestinal disorders. The primary endpoint is the AIMS at the end of the six weeks of dosing. This study continues to enroll patients, and top-line data from this study is expected in the fourth quarter of 2013.

The Company plans to request an end of Phase II meeting with the FDA for NBI-98854 in tardive dyskinesia during the fourth quarter of 2013.

The Company is also in the process of initiating two Phase I studies for NBI-98854 assessing drug-drug interactions as well as the impact of hepatic impairment on drug metabolism. Both of these studies will be completed prior to the start of Phase III and will support the planned NDA filing.

Additionally, the Company has initiated preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome. Upon successful completion of these preclinical studies, the Company anticipates entering Phase I and Phase II clinical studies in 2014.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Easter
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
3. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
4. Neurocrine Biosciences Reports Second Quarter 2012 Results
5. Neurocrine Biosciences Reports Third Quarter 2012 Results
6. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
7. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
8. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
9. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
10. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
11. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Rochelle, N.Y. (PRWEB) August 21, 2014 ... is the first private college in the Mid-Hudson Region ... College will now begin accepting applications from qualified “high-technology” ... , “We are very pleased to have been selected ... support Governor Cuomo’s transformative initiative to stimulate economic development ...
(Date:8/21/2014)... , Aug. 21, 2014 Mathematic studies at ... Harvard University , and funded by the Jeffrey Epstein ... within tumors can be visually identified for elimination. These aggressive ... The study, which shows a topological map of what to ... in cancer research, for while tumor cells can be extracted ...
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... June 7, 2011 DuPont (NYSE: DD ... investors at the JPMorgan Diversified Industries Conference to expect ... innovation, selective investment in attractive areas, broad-based growth, especially ...  Kullman also reaffirmed DuPont,s 2011 earnings per share (EPS) ...
... its origins in Hamburg. Jrg Weimller, a materials scientist ... Helmholtz Center Geesthacht, has carried out research on this ... Institute for Metal Research in Shenyang, China., The 51-year-old ... which opens the door to a multitude of diverse ...
... of Academic Health Centers (AAHC) supports the Department ... Rights, (OCR) proposed rule, issued last week, furthering ... efforts to alleviate unnecessary compliance and administrative burdens ... placed on covered entities, and applauds its efforts ...
Cached Biology Technology:DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 3Hard or soft: At the touch of a button 2Hard or soft: At the touch of a button 3AAHC Commends HHS Office for Civil Rights HIPAA Privacy Proposal 2
(Date:8/21/2014)... Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication ... today that its shares of common stock and the ... its proposed underwritten public offering of common stock and ... Capital Market, subject to closing of its proposed underwritten ... will trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... Bacteria growing in near darkness use a previously unknown ... a research team led by a Penn State University ... further research aimed at improving plant growth, harvesting energy ... now occurring on Lake Erie and other lakes worldwide. ... the Science Express edition of the journal ...
(Date:8/21/2014)... might seem easy to ignore, but they are the ... depend upon. Humans are increasingly dependent on algae, too, ... and sink it to the bottom of the ocean. ... laboratory experiments, researchers have evidence showing that viruses infecting ... algae,s blooms, even when all else stays essentially the ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Viruses take down massive algal blooms, with big implications for climate 2
... the University of York have played a crucial role ... up land contaminated by explosives. , The research, by ... (Centre for Novel Agricultural Products) in the University's Department ... trees and plants into highly-effective pollution-busters. The research findings ...
... can harm the brain immediately after a stroke may actually ... the study could change the way stroke is treated, extending ... to a couple of weeks. The results may suggest new ... team from the Harvard Medical School Departments of Radiology and ...
... Medical Center researchers Massimo Trucco, MD, and Nick Giannoukakis, ... model by a novel treatment strategy involving specific modification ... in animal studies. , The U.S. Food and Drug ... to evaluate the safety and feasibility of the treatment ...
Cached Biology News:York researchers develop pollution-busting plants to clean up contaminated land 2'Bad' enzymes may wear white hats after stroke 2'Bad' enzymes may wear white hats after stroke 3'Bad' enzymes may wear white hats after stroke 4Researchers reverse juvenile diabetes in animal model 2Researchers reverse juvenile diabetes in animal model 3Researchers reverse juvenile diabetes in animal model 4
Acetylcholinesterase (human brain, AChE)...
... Microsomal vesicles are used to study ... proteins. Processing events such as signal ... core glycosylation can be examined by ... in vitro in the presence of ...
Polio component type I...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Biology Products: